Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10013213HBVENSG00000126218.12protein_codingF10NoNo2159P00742
Q5JVE7
Q5JVE8
TVIS10020895HBVENSG00000126218.12protein_codingF10NoNo2159P00742
Q5JVE7
Q5JVE8
TVIS30020164HIVENSG00000126218.12protein_codingF10NoNo2159P00742
Q5JVE7
Q5JVE8
TCGA Plot Options
Drug Information
GeneF10
DrugBank IDDB01225
Drug NameEnoxaparin
Target IDBE0000216
UniProt IDP00742
Regulation Typeinhibitor
PubMed IDs17474542; 17509040; 16187968; 15675440; 17567541
CitationsGraff J, Picard-Willems B, Harder S: Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007 Apr;45(4):237-43.@@Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P: Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol. 2007 Oct;64(4):428-38. Epub 2007 May 17.@@Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G: Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005 Oct;60(4):364-73.@@Dalmora SL, Junior LB, Schmidt CA, Vaccari SF, Oliveira PR, Codevilla CF: Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations. J AOAC Int. 2004 Nov-Dec;87(6):1305-8.@@Paige JT, Gouda BP, Gaitor-Stampley V, Scalia PG, Klainer TE, Raum WJ, Martin LF: No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):469-75. Epub 2007 Jun 12.
GroupsApproved
Direct Classification
SMILES
Pathways
PharmGKBPA449463
ChEMBLCHEMBL1201685